News

The development and implementation of evidence-based appropriateness criteria may help reduce costs associated with an increase in elective procedures.

A think-tank report calls for national agenda to hold spending down to the growth in GDP per capita

ARBs and ACE inhibitors prolong life and help patients maintain daily living activities.

The new middle class represents an opportunity to sell health insurance products outside the United States

Hospitals have not gotten a break in the budget battles but few are changing their financial strategy

Among the list of changes that consumers simply are not ready to face is value-based purchasing and reduced care based on evidence

Quality rating processes will begin in 2016 for insurance exchanges, and iindustry groups recommend using current measures

In partnership with the Mayo Clinic, a UnitedHealthcare unit is putting data to work in a new facility to drive improved outcomes

Five key functions must be included in your provider-facing portal

Navigators will be the boots on the ground helping millions of Americans enroll in exchange plans

Predictive analysis can link suspicious behavior back to fraudsters before claims are paid out

AHA notes that four out of five seniors have chronic conditions

The Medicaid program currently covers 60 million people, but it's about explode in terms of cost and enrollment

Canagliflozin is a sodium glucose co-transporter inhibitor under review for FDA approval for the treatment of type 2 diabetes mellitus.

Patients who take a combination of diuretics and either angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and add NSAIDs, have an increased risk of acute kidney injury, according to a study online in BMJ.

Polypharmacy screening has the significant potential to improve medication safety.

FDA and the Federal Trade Commission (FTC) issued a warning letter to Flu and Cold Defense LLC (Boca Raton, Fla.) for making misleading, unproven claims about its GermBullet inhaler, and said the company has been marketing an untested inhaled formula as a flu remedy in violation of drug safety regulations.

FDA has approved mipomersen sodium (Kynamro, Genzyme and Isis Pharmaceuticals) once-a-week injection as an addition to lipid-lowering medications and diet to treat patients with a rare type of high cholesterol called homozygous familial hypercholesterolemia (HoFH). The addition of Kynamro helps to reduce low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol (non HDL-C).

The public is generally satisfied with cancer research progress over the past 20 years. However, they believe it takes too long for new cancer drugs to reach patients and that their countries invest too little in fighting cancer, according a global survey.

Recent FDA action (through January 2013) related to, IPX066, Afatinib, Enobosam, GTx-024, Elafin, Ezatiostat HCL, Tranexamic acid tablets, Lamotrigine extended-release tablets

New molecular entity: A benzodiazepine indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients age 2 years or older.

Recent FDA Approvals (through January 2013) related to (Deferasirox, Exjade, Novartis, bevacizumab, Avastin, Roche Group, trivalent influenza vaccine, Flublok, Protein Sciences, Budesonide, Uceris, Santarus, pooled plasma blood product, Octaplas, Octapharma, Sumatriptan iontophoretic transdermal system, Zecuity, NuPathe, onabotulinumtoxinA, Botox, Allergan

A look at the evidence in support of supplemental vitamin use during pregnancy.

Diabetes mellitus is a chronic condition characterized by elevated blood glucose that occurs as a result of impaired insulin action or production. This article focuses on current recommendations for the treatment of type 2 diabetes and methods of controlling co-occurring conditions.

The specialty pharmaceutical market is currently fragmented with extreme variation in knowledge/education, patient care management, service, and outcomes.

Optum and Mayo Clinic have partnered to launch Optum Labs, an open facility designed to enable collaborative research and innovation focused on better patient care.

Treatment of advance kidney cancer has evolved considerably over the last decade, and multiple agents are available.

A stool substitute therapy has promise as an approach to eradication of refractive Clostridium difficile (C difficile) in a proof-of-principle study published January 9 in the inaugural issue of Microbiome.